FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Cohance Lifescience FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with six observations from an inspection at the Cohance Lifesciences drug manufacturing facility in ...

Senators Want Overseas Drug Inspection Info

[ Price : $8.95]

Sens. Rick Scott and Kirsten Gillibrand ask FDA commissioner Martin Makary to answer 11 questions about the agencys oversight of o...

Olympus Recalls ViziShot 2 FLEX Needles

[ Price : $8.95]

Olympus recalls (Class 1) its ViziShot 2 FLEX (19G) EBUS-TBNA needles manufactured before 5/12 after receiving reports of device c...

FDA Alert on Abiomed Impella Controllers

[ Price : $8.95]

FDA issues an early alert after becoming aware that Abiomed had issued a letter to affected customers recommending certain Automat...

FDA Rejects Biogen's High-Dose Spinraza

[ Price : $8.95]

FDA issues Biogen a complete response letter on a supplemental NDA for a high-dose regimen of Spinraza (nusinersen) for treating s...

FDA Extends Review on Sanofi Multiple Sclerosis NDA

[ Price : $8.95]

FDA extends by three months its review of Sanofis multiple sclerosis drug tolebrutinib to evaluate additional analyses submitted r...

Roches Giredestrant Shows Promise in Breast Cancer

[ Price : $8.95]

Roche reports positive Phase 3 data with its investigational breast cancer drug giredestrant.

FDA Issues Guidance on Malaria Drug Development

[ Price : $8.95]

FDA posts a draft guidance entitled Malaria: Developing Drugs for Treatment that outlines key considerations for companies develop...

Lexicon Submits New Data to FDA on Zynquista

[ Price : $8.95]

Lexicon Pharmaceuticals says FDA is requiring additional time to review its new clinical data submitted earlier this month in an e...

Priority Review for Rare Vision-Loss Disorder Drug

[ Price : $8.95]

FDA accepts for priority review a Chiesi NDA for idebenone and its use in treating Leber hereditary optic neuropathy.